Dinleyici Ener Cagri, Ciftci Ergin, Somer Ayper, Yilmaz Dilek, Tezer Hasan
Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkiye.
Faculty of Medicine, Department of Pediatric Infectious Disease, Ankara University, Ankara, Turkiye.
Hum Vaccin Immunother. 2025 Dec;21(1):2516949. doi: 10.1080/21645515.2025.2516949. Epub 2025 Jun 10.
remains a major global health concern, causing invasive meningococcal disease (IMD) with significant morbidity and mortality. Despite vaccination efforts, Nm serogroup prevalence and antibiotic resistance continue to evolve, necessitating ongoing surveillance and novel immunization strategies. This review aims to assess the role of MenACWY-TT, a quadrivalent meningococcal conjugate vaccine, in IMD prevention by evaluating its immunogenicity, safety, and real-world effectiveness. The objectives include analyzing its advantages over existing vaccines, identifying gaps in long-term immunity data, and assessing its potential integration into National Immunization Programs (NIPs). MenACWY-TT has demonstrated strong immunogenicity, a favorable safety profile, and ease of administration with its liquid, non-adjuvanted formulation. Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations.
仍然是一个主要的全球卫生问题，可引发侵袭性脑膜炎球菌病（IMD），具有显著的发病率和死亡率。尽管进行了疫苗接种工作，但脑膜炎奈瑟菌血清群的流行情况和抗生素耐药性仍在不断演变，因此需要持续监测并采取新的免疫策略。本综述旨在通过评估四价脑膜炎球菌结合疫苗MenACWY-TT的免疫原性、安全性和实际效果，来评估其在预防IMD中的作用。目标包括分析其相对于现有疫苗的优势、确定长期免疫数据中的差距，以及评估其纳入国家免疫规划（NIPs）的潜力。MenACWY-TT已显示出强大的免疫原性、良好的安全性，并且其液体、无佐剂配方易于接种。实际研究表明其具有很高的疫苗效力和群体保护效益。然而，需要进一步研究以评估高危人群的长期免疫和疗效。
